Work at Alicorn Pharmaceutical Co. Ltd. has led to the synthesis of new sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers. They are reported to be useful for the treatment of pain, respiratory and neurological disorders.

Sea4us - Biotecnologia e Recursos Marinhos Lda. has reported oxazolidone-derived compounds potentially useful for the treatment of chronic pain.

Opioids are widely used to relieve the pain associated with oral squamous cell carcinoma (OSCC), but tolerance and undesired effects often limit their use. EGFR is commonly amplified in oral cancer and its involvement in OSCC-associated pain and opioid tolerance was investigated through the sensitization of trigeminal ganglion cells, which are the main sensory neurons that innervate the face and mouth. For this purpose, they used the EGFR inhibitor AG-1478, which was tested in vitro as well as in in vivo in human OSCC and an orthotopic murine models.

Humanwell Pharmaceutical US Inc. has disclosed prodrugs of somatostatin SST4 receptor agonists described as potentially useful for the treatment of visceral and neuropathic pain.

Jumpcan Pharmaceutical Group Ltd. has divulged sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain.

Chengdu Easton Biopharmaceuticals Co. Ltd. has divulged sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain, arrhythmia, cough, urinary incontinence and multiple sclerosis.

Alphamol Science Ltd. has divulged opioid receptor agonists reported to be useful for the treatment of pain.

Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have divulged aromatic compounds acting as sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain.